| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02377401 | Influenza, Human | Drug: Zanamivir | GlaxoSmithKline | Phase 1 | 2015-04-01 | 2016-02-08 |
| NCT01527110 | Influenza, Human | Drug: Intravenous (IV) zanamivir | GlaxoSmithKline | Phase 3 | 2012-01-01 | 2017-01-25 |
| NCT01390792 | Influenza, Human | Drug: Zanamivir hydrate | GlaxoSmithKline | | 2007-01-01 | 2011-07-14 |
| NCT00540501 | Healthy Subjects | Drug: Oseltamivir and Intravenous Zanamivir | GlaxoSmithKline | Phase 1 | 2007-10-01 | 2010-05-27 |
| NCT00784784 | Influenza | Biological: Fluviral|Drug: Zanamivir | Mount Sinai Hospital, Canada|GlaxoSmithKline | Phase 3 | 2008-11-01 | 2014-11-07 |
| NCT01014988 | Influenza, Human | Drug: zanamivir aqueous solution | GlaxoSmithKline | Phase 2 | 2009-11-01 | 2016-08-12 |
| NCT01231620 | Influenza, Human | Drug: Zanamivir|Drug: Placebo to match zanamivir|Drug: Oseltamivir|Drug: Placebo to match oseltamivir | GlaxoSmithKline | Phase 3 | 2011-01-01 | 2017-01-16 |
| NCT01462487 | Influenza, Human | Drug: Treatment with zanamivir | GlaxoSmithKline | | 2011-07-01 | 2014-04-17 |
| NCT01199744 | Influenza, Human | Drug: zanamivir | GlaxoSmithKline | | 2009-11-01 | 2011-11-17 |
| NCT00921726 | Influenza|Virus Diseases | Drug: Zanamivir|Drug: Oseltamivir | National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health | Phase 1 | 2009-07-01 | 2010-03-18 |
| NCT00989404 | Influenza A Virus, H1N1 Subtype | Drug: Zanamivir|Drug: Zanamivir|Drug: Zanamivir | GlaxoSmithKline | Phase 1 | 2009-10-01 | 2016-10-11 |
| NCT00799760 | Gastric Influenza | Drug: oseltamivir + zanamivir|Drug: oseltamivir + zanamivir's placebo|Drug: oseltamivir's placebo + zanamivir | Assistance Publique - Hpitaux de Paris|Hoffmann-La Roche|GlaxoSmithKline | Phase 3 | 2008-12-01 | 2012-03-16 |
| NCT01459081 | Influenza A Virus Infection|Influenza B Virus Infection | Drug: Zanamivir|Drug: Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 3 | 2011-10-01 | 2013-01-15 |
| NCT00980109 | Influenza | Drug: active oseltamivir|Drug: placebo capsule|Drug: zanamivir for inhalation|Drug: placebo for inhalation | University of Oxford|National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | 2009-09-01 | 2010-09-21 |
| NCT00979667 | Upper Respiratory Tract Infection|Influenza | Drug: Oseltamivir|Drug: Zanamivir|Drug: Placebo of Oseltamivir | Chinese University of Hong Kong|Food and Health Bureau, Hong Kong|Hospital Authority | Phase 3 | 2009-10-01 | 2011-04-08 |
| NCT01156701 | Pulmonary Disease, Chronic Obstructive|Bronchospasm|Influenza, Human|Asthma|Respiratory Disease|Exacerbation of COPD|Bronchitis|Otitis Maedia|Pneumonia|Sinusitis | Drug: Receiving a prescription of Relenza for prophylaxis|Other: No prophylaxis with Relenza | GlaxoSmithKline | | 2009-07-01 | 2011-06-02 |
| NCT01353729 | Influenza, Human | Drug: 600 mg zanamivir + moxifoxacin placebo|Drug: 1200 mg zanamivir + moxacin placebo|Drug: zanamivir placebo + moxifloxacin placebo|Drug: zanamivir placebo + 400 mg moxifloxacin | GlaxoSmithKline | Phase 1 | 2011-05-01 | 2016-11-30 |
| NCT01353768 | Infections, Respiratory Tract | Other: retrospective chart review | GlaxoSmithKline | | 2011-07-01 | 2016-11-21 |
| NCT00830323 | Influenza A Infection | Drug: oseltamivir + zanamivir|Drug: oseltamivir+ amantadine|Drug: oseltamivir | Hospices Civils de Lyon | Phase 2 | 2009-01-01 | 2010-09-29 |
| NCT00867139 | Influenza | Drug: TCAD|Drug: Zanamivir or Oseltamivir|Other: Open label treatment with TCAD | Fred Hutchinson Cancer Research Center | Phase 1|Phase 2 | 2009-03-01 | 2013-08-08 |
